MECHANISMS OF ACTION AND RESISTANCE TO ICRF187

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Abstract

The objective of this project is to characterize the mechanism(s) of resistance to the bisdioxopiperazine class of DNA topoisomerase II (topo II) catalytic inhibitors. Compared to parental CHO cells, a subline (DZR) with acquired resistance to dexrazoxane (ICRF-187) exhibits no change in topo II catalytic activity but shows a dramatic decrease in the ability of ICRF-187 to: 1) interfere with initial formation of VP-16-induced topo II-DNA complexes; 2) "chase-out" preformed VP-16- induced topo II-DNA complexes. We hypothesize that the stable acquired resistance phenotype to ICRF-187 in DZR is due to changes in topo II structure/function that alters its interactions with DNA and/or drugs. Specific Aims are to: 1. determine the molecular basis for DZR cells resistance to ICRF-187 by sequencing of topo II cDNA and to demonstrate further the biochemical mechanism(s) of bisdioxopiperazine resistance. 2. synthesize and utilize a photoactivatible VP-16 analog for the study of ICRF-187 mechanisms of action and resistance. 3. test the hypothesis that ICRF-187 inhibition of topo II will upregulate DNA topoisomerase I levels and sensitize cells to inhibitors such as topotecan. Results obtained will establish more precisely the mechanism of action of drugs that inhibit topo II without inducing topo II-DNA cleavable complexes and will lead to strategies for clinical use of these agents alone or in combination with other topoismerase inhibitors.